VAGINAL CARCINOMA

EXAMPLE OF A VAGINAL CARCINOMA USING PROPOSED TEMPLATE

- Case: Squamous cell carcinoma arising in VAIN 3, right side of vagina, lower third
- Wide-local excision of involved area
- Right inguinal sentinel lymph node (negative)
- Tumor Size = 2.4 x 1.0 x 0.8 cm
- ALI+
- PNI+
- Depth 0.8 cm
- Margins negative, closest margin, deep margin, by 0.3 cm

CARCINOMA OF THE Vagina:

1. Specimens: Right vagina
2. Procedures: Wide-local excision
3. Sentinel Lymph Node Sampling: Performed; right inguinal sentinel lymph node biopsy
4. Regional Lymph Node Sampling: Not performed
5. Specimen Integrity: Intact
6. Primary Tumor Site: Right vagina, lower third
7. Tumor Size:
   a. Greatest dimension: 2.4 cm
   b. Total dimensions: 2.4 x 1.0 x 0.8 cm
8. Tumor Focality: Unifocal
9. Histologic Type: Squamous cell carcinoma, non-keratinizing type
10. Histologic Grade: Moderately-differentiated (grade 2)
11. Stromal Invasion: Present; 0.8 cm
12. Lymph-Vascular Space Invasion: Present
13. Perineural Invasion: Present
14. Other Sites/Organs Involved: Negative
15. Additional Pathologic Findings: High-grade squamous intraepithelial lesion (HSIL)
16. Sentinel Lymph Nodes: Negative; 0/1 (right inguinal sentinel lymph node)
17. Total Lymph Nodes: Negative; 0/1
18. Cytology: Not performed
19. Surgical Margins: Negative
20. Pathologic Staging: AJCC [pT1 N0(sn)]; FIGO [I]
CARCINOMA OF THE VAGINA (specific details to be added into SOFT)

1. **Specimen(s):** list all specimens removed during case

2. **Procedure(s):** select all that apply
   a. [Incisional biopsy]
   b. [Excisional biopsy]
   c. [Wide-local excisional biopsy]
   d. [Radical vaginectomy]
   e. [Partial vaginectomy]
   f. [Vaginectomy] (can further specify, e.g. “anterior vaginectomy”)

3. **Sentinel Lymph Node Sampling:** select whether or not sentinel lymph nodes were removed
   a. [Performed]
   b. [Not performed]
   c. [Not applicable]
   d. [Cannot be determined]

4. **Regional Lymph Node Sampling:** select whether or not regional, non-sentinel lymph nodes were removed
   a. [Performed]
   b. [Not performed]
   c. [Cannot be determined]

5. **Specimen Integrity:** document whether intact or received fragmented. This absolutely requires correlating with the operative report

6. **Primary Tumor Site:** select all that apply
   a. [Upper third]
   b. [Middle third]
   c. [Lower third]
   d. [Cannot be determined]

7. **Tumor Size:** provide greatest dimension and total dimensions
   a. [Greatest dimension: <SPECIFY>]
   b. [Total dimensions: <SPECIFY>]
   c. [Cannot be determined]

8. **Tumor Focality:** specify tumor focality
   a. [Unifocal]
   b. [Multifocal]
   c. [Cannot be determined]

9. **Histologic Type:** select appropriate tumor type
   a. [Squamous cell carcinoma, keratinizing type]
   b. [Squamous cell carcinoma, non-keratinizing type]
   c. [Squamous cell carcinoma, basaloid type]
   d. [Squamous cell carcinoma, papillary type]
e. [Verrucous carcinoma]
f. [Paget disease, <SPECIFY INVASIVE OR NON-INVASIVE>]
g. [Adenocarcinoma, intestinal type]
h. [Mesonephric carcinoma]
i. [Clear cell carcinoma]
j. [Mucinous carcinoma]
k. [Endometrioid carcinoma]
l. [Adenosquamous carcinoma]
m. [Undifferentiated carcinoma]
n. [Carcinoma, not-otherwise-specified]
o. [Other, <SPECIFY>]

10. **Histologic Grade**: specify histologic grade of tumor
   a. [Well-differentiated (grade 1)]
   b. [Moderately-differentiated (grade 2)]
   c. [Poorly-differentiated (grade 3)]
   d. [Undifferentiated (grade 4)]
   e. [Other, <SPECIFY>]
   f. [Not applicable]

11. **Stromal Invasion**: specify presence of stromal invasion
   a. [Absent]
   b. [Present, <PROVIDE DEPTH OF INVASION>]

12. **Lymph-Vascular Space Invasion**: state whether LVI is present
   a. [Absent]
   b. [Present]
   c. [Suspicious]
   d. [Cannot be determined]

13. **Perineural Invasion**: state whether PNI is present
   a. [Absent]
   b. [Present]
   c. [Suspicious]
   d. [Cannot be determined]

14. **Other Sites/Organs Involved**: state whether there is disease outside the vagina
   a. [Negative]
   b. [Positive: <LIST OTHER ORGANS INVOLVED>; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>]

15. **Additional Pathologic Findings**: if possible, select all that apply
   a. [None identified]
   b. [Low-grade squamous intraepithelial lesion (LSIL)]
   c. [High-grade squamous intraepithelial lesion (HSIL)]
   d. [Adenosis]
16. Sentinel Lymph Nodes: provide sentinel lymph node status
   a. [Not performed]
   b. [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>] (specify site of sentinel lymph node)
   c. [Positive: <PROVIDE TOTAL NUMBER OF POSITIVE SENTINEL LYMPH NODES> / <PROVIDE TOTAL SENTINEL LYMPH NODES>] (specify site of sentinel lymph node)
   d. [Extranodal extension: <STATE IF EXTRANODAL EXTENSION IS PRESENT OR ABSENT>]

17. Total Lymph Nodes: provide total sentinel and non-sentinel lymph node status
   a. [Not performed]
   b. [Negative: 0 / <PROVIDE TOTAL SENTINEL AND NON-SENTINEL LYMPH NODES>]
   c. [Positive: <PROVIDE TOTAL NUMBER OF POSITIVE SENTINEL AND NON-SENTINEL LYMPH NODES> / <PROVIDE TOTAL NUMBER OF SENTINEL AND NON-SENTINEL LYMPH NODES> ; <PROVIDE SIZE OF LARGEST LYMPH NODE METASTASIS AND IF THERE IS EXTRANODAL EXTENSION>]

18. Cytology: state whether or not cytology was performed and results, include accession number
   a. [Not performed]
   b. [Performed]:
      i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
      ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]

19. Surgical Margins: select appropriate margin status
   a. [Negative for carcinoma] (use if there is no significant background SIL or D-VAIN)
   b. [Negative for invasive and in-situ carcinoma] (use if there is significant background SIL or D-VAIN)
   c. [Positive for invasive carcinoma; <STATE SPECIFIC MARGIN>, <STATE FOCAL OR DIFFUSE>, <PROVIDE APPROXIMATE LINEAR EXTENT>]
   d. [Positive for in-situ carcinoma only; <STATE SPECIFIC MARGIN>, <STATE FOCAL OR DIFFUSE>, <PROVIDE APPROXIMATE LINEAR EXTENT>]
   e. [Cannot be determined]

20. Pathologic Staging: may use AJCC and/or FIGO; refer to staging manuals
*Primary endometrioid tumors of the vagina must be distinguished from recurrent/metastatic endometrioid adenocarcinoma of uterine primary.  

* Non-epithelial vaginal malignancies include mesenchymal (sarcoma botryoides, leiomyosarcoma, endometrial stromal sarcoma, aggressive angiomyxoma, etc), melanocytic, and germ cell tumors. Grading and staging of these tumors is not included in the TNM system for the vagina and instead may use different grading and staging schema.